注册 | 登录 | 充值

返回首页
找到约 212 条结果

APPROACH研究:罗格列酮对有心血管病史的2型糖尿病患者动脉粥样硬化进展的干预研究

试验设计:糖尿病患者被随机分成逐渐增加至每天8 mg的罗格列酮组(n=333)和逐渐增加至每天15 mg的格列吡嗪组(n=339)。在起始和18个月时行血管内超声检查。结果    ● 粥样斑块变化百分比:罗格列酮组-0.21%,格列吡嗪组0.43% (P...... 
学术资讯 - 临床研究

SAPPHIRE:动脉内膜切除术高风险患者保护性支架置入术和血管修复术的研究3年的结果

SAPPHIRE    试验设计:严重颈内动脉狭窄的高手术风险患者随机分为栓塞保护下颈动脉支架置入术组(n=167)和动脉内膜切除术(CEA)组(n=167),随访3年。结果    ● 30天内死亡、脑卒中和心肌梗死(MI)以及31天~3年内死亡和同...... 
学术资讯 - 临床研究

[ASH2008]ASCOT

A.K. Gupta, N.R. Poulter, S. Eldridge, J. Dobson, M. Caulfield, F.P. Cappuccio, D. Collier, C.J. Griffiths, H. Hemingway, J.K. Cruickshank, P.S. Sever, G.S. Feder Imperial College London, United King..... 
学术资讯 - 临床研究

为什么药企做了那么多的app和微信号都无人问津?

为什么药企做了那么多的app和微信号都无人问津? 作者Dr.2,珍立拍股份公司董事长             这个标题既是一个疑问,也是一个结果,其实这..... 
学术资讯 - 医疗政策

Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial.

Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Fail..... 
学术资讯 - 临床研究

glucose

Department of Medicine, McMaster University, and Population Health Research Institute, Hamilton General Hospital, Hamilton, Canada. yusufs@mcmaster.caBACKGROUND: Approximately 15.5 million deaths from cardiovascular..... 
学术资讯 - 临床研究

CREATE

Department of Medicine, McMaster University, and Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada. smehta@mcmaster.caCONTEXT: Glucose-insulin-potassium (GIK) infusion is a w..... 
学术资讯 - 临床研究

IDEAL试验:高剂量阿托伐他汀和常规剂量辛伐他汀在心肌梗死后二级预防的对比研究——IDEAL随机对照试验研究

Context Evidence suggests that more intensive lowering of low-density lipoprotein cholesterol (LDL-C) than is commonly applied clinically will provide further benefit in stable coronary artery dis..... 
学术资讯 - 临床研究

Effect of Glucose

JAMA. 2005;293:437-446. The CREATE-ECLA Trial Group Investigators Context: Glucose-insulin-potassium (GIK) infusion is a widely applicable, low-cost therapy that has been postulated to improve mortality in pat..... 
学术资讯 - 临床研究

疫苗类APP新格局

疫苗类APP新格局 作者:唐京燕             作者:唐京燕,秀红资本的合伙人,CFA,专注于企业并购和投资。 多年以来,无论是媒体还是公众,对疫苗和..... 
学术资讯 - 医疗政策